ALTO-207

ALTO-207 is Alto Neuroscience's Phase 2b investigational combination for treatment-resistant depression (TRD), pairing pramipexole, a decades-old Parkinson's drug that activates dopamine receptors, with ondansetron, the generic anti-nausea drug that blocks a specific serotonin receptor. The 178-patient placebo-controlled trial NCT07553637 is actively recruiting adults with TRD on a stable baseline antidepressant, with an eight-week double-blind treatment period and change in MADRS as the primary endpoint [1]. The commercial logic is straightforward: both components are cheap generics with long safety files, and pramipexole produced a large signal (Cohen's d=0.87 at 12 weeks) in the UK investigator-led PAX-D trial, giving Alto a mechanism with human proof-of-concept that Alto itself describes as more than twice the effect size of currently approved TRD therapies [5]. The scientific logic is dirtier. Alto's prior lead ALTO-100 missed in a Phase 2b MDD study in late 2024, which cratered the stock and reset expectations for the whole EEG-biomarker platform [2]. The investment framing has also shifted. Following a successful FDA meeting in late 2025, Alto plans to initiate Phase 3 by early 2027 on alignment with FDA, in parallel with the ongoing Phase 2b [8]. That means the Phase 2b is less a binary go/no-go gate and more a confirmatory signal and dose/safety read running alongside pivotal planning. The readout matters disproportionately to Alto, but a miss would not automatically kill the Phase 3 program the FDA has already aligned on.

ALTO-207 is not a novel chemical entity. It is a fixed-dose combination of two drugs already approved and genericized in other indications: pramipexole (approved in the US in 1997 for Parkinson's disease and later for restless legs syndrome) and ondansetron (approved in 1991 for chemotherapy-induced nausea). The combination itself is investigational and would require its own NDA, since FDA treats fixed-dose combinations as distinct products rather than compounded generics. No FDA expedited designations (breakthrough, fast track, orphan, RMAT) have been disclosed in Alto's SEC filings covering 2025 and 2026 [3]. What has been disclosed is more consequential: Alto announced in late 2025, following a successful FDA meeting, that it would accelerate ALTO-207 development, initiate a potentially pivotal Phase 2b in H1 2026, and launch Phase 3 by early 2027 on FDA alignment [8]. Phase 2b status was confirmed on ClinicalTrials.gov under NCT07553637, with recruiting status, a 178-patient enrollment target, and an eight-week double-blind treatment period [1]. Alto also disclosed in 2026 that an additional Phase 3 monotherapy trial of ALTO-207 is planned alongside the adjunctive Phase 2b [9]. Expected topline from the Phase 2b is guided by the company to H2 2027. The implication is that Phase 3 initiation is not contingent on a clean Phase 2b readout. The Phase 2b is a confirmatory and operational read running in parallel with pivotal design work, not a binary gate. Any 2026 catalyst for Alto on this asset will be enrollment updates and interim operational color on earnings calls, not clinical data.

Dopamine is the brain's motivation and reward signal. In depression, especially the kind that doesn't respond to standard serotonin-boosting SSRIs, patients often describe not feeling anything, called anhedonia, which maps better onto a dopamine deficit than a serotonin one. Pramipexole directly activates the D2 and D3 dopamine receptors, mimicking dopamine itself at receptors concentrated in reward circuitry [4]. That rationale is backed by human evidence: the UK PAX-D trial reported that adjunctive pramipexole produced a large improvement in depression severity relative to placebo in TRD patients already on antidepressants, with a Cohen's d of 0.87 at 12 weeks and a high but tolerable adverse event rate [5]. The ondansetron piece is less obvious. Ondansetron blocks 5-HT3, a serotonin receptor that, unlike most serotonin receptors, acts as an ion channel and sits on neurons involved in gut-brain signaling and cognition. The hypothesis is twofold. First, 5-HT3 blockade may mute pramipexole's biggest tolerability problem, nausea, which drives dropout at antidepressant-relevant doses. Second, 5-HT3 antagonism itself has shown weak but reproducible pro-cognitive and mood signals in small trials. Open Targets scores D2 as a top-five target for major depressive disorder (evidence 0.743), reflecting a decade of genetic and pharmacologic data linking dopamine signaling to mood [6]. The combination is mechanistically coherent. Whether the ondansetron contribution is additive or just a tolerability patch is an open question the Phase 2b will not fully answer.

The study is NCT07553637, a Phase 2b randomized placebo-controlled trial of ALTO-207 in adults with TRD, defined by Alto as two to five prior treatment failures in the current episode with a baseline MADRS of at least 25, run adjunctively while patients remain on their baseline antidepressant through an eight-week double-blind treatment period [1]. Enrollment target is 178 participants. The primary endpoint is change from baseline in MADRS total score, the standard clinician-rated depression scale in TRD trials, which keeps the readout comparable to Spravato, Auvelity, and the pipeline of psychedelic programs. The important design context is that this Phase 2b is not a conventional sequential signal-finding Phase 2. Alto has publicly guided that it is pivotal-adjacent, running concurrently with Phase 3 design alignment under an FDA agreement reached in late 2025, with Phase 3 initiation expected in early 2027 [8]. Alto's platform premise is biomarker-selected enrollment using EEG and behavioral signatures, but whether ALTO-207 is being run with a prespecified biomarker-enriched arm or an all-comers TRD design is not disclosed in the public registry fields. The 178-patient size is powered for roughly 3 to 4 points of placebo-adjusted MADRS separation. PAX-D delivered an effect roughly two to three times that size (d=0.87 translates to approximately 7 to 9 MADRS points at observed scale) [5], so if the mechanism translates, this trial is overpowered and should read out conclusively. If translation is lossy, which is normal for investigator-led to industry trials, the effect could compress toward the powered zone and still succeed. The parallel Phase 3 track insulates Alto from a borderline Phase 2b outcome in a way that unusual for an asset at this stage.

Our model estimates a 3% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is primary. TRD trials show large placebo responses, often 8 to 10 points on MADRS, which has killed otherwise promising mechanisms. Pramipexole's PAX-D signal was large (d=0.87) but came from a UK investigator-led trial with a specific titration schedule and patient population [5]. Translating that into a US registrational-track study with a different sponsor, dose titration, and population is not guaranteed. If Alto has not biomarker-enriched the ALTO-207 trial, it is competing on raw mechanism against the same high placebo response that sank numerous augmentation strategies. Safety risk is manageable but not zero. Pramipexole carries labeled risks of impulse control disorders (pathological gambling, hypersexuality) and sudden-onset somnolence, both more concerning in a non-Parkinson's TRD population that is younger and employed. Ondansetron carries a QT prolongation signal that led the FDA to limit the single IV dose in 2012. The combination's QT and impulse-control profile in a 178-patient Phase 2b over eight weeks is unlikely to produce a definitive answer. Execution risk is lower than it was. Alto raised approximately $50 million in a PIPE in October 2025 and closed an additional roughly $100 million financing in July 2026, bringing pro forma cash to about $338 million and funded operations through 2030 per company disclosures [9]. The cash runway question has shifted from survival-to-readout to whether a Phase 3 program (including the recently announced monotherapy Phase 3) is commercially viable at successful outcome. Commercial risk is real even on success. Both components are generic. A patented fixed-dose combination can be marketed, but payers will press hard on why clinicians cannot just prescribe the two generics off-label, which is the exact dynamic that stalled Auvelity's early launch.

Worth watching, with the signal-to-noise caveat that Alto specifically carries platform risk after the ALTO-100 Phase 2b miss [2]. The specific data point that converts ALTO-207 from noise to signal is a MADRS placebo-adjusted separation large enough to be consistent with PAX-D's effect size, ideally with a prespecified population Alto can defend as replicable. The important reframe versus a conventional Phase 2 asset is that Phase 3 is already on the calendar for early 2027 on FDA alignment [8]. A borderline Phase 2b miss would not necessarily kill the Phase 3 program, though it would compress valuation and raise questions about biomarker-selection lift. A clean positive would substantially re-rate the asset and the platform. The next check-in is Alto's Q4 2026 earnings call for enrollment pace and any guidance on topline timing within the H2 2027 window. The deeper read on this program is about the TRD field, not Alto. Spravato (esketamine) crossed into blockbuster territory, with J&J reporting approximately $1.3 billion in 2024 revenue, Auvelity is scaling, and multiple psychedelic programs including Compass Pathways' psilocybin and MindMed's LSD-based candidates are in late-stage trials. The commercial window for a cheap-generic-combination with a modest effect size is narrower than it was five years ago, but PAX-D's d=0.87 is not a modest effect. If ALTO-207 reproduces even half that in a controlled industry trial, it is a validation of dopaminergic augmentation as a durable TRD strategy and a reason to re-rate the broader D2/D3 investigational field. The H2 2027 Phase 2b readout is the primary catalyst, but the Phase 3 initiation signal in early 2027 is a legitimate interim catalyst in its own right.